FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2965794037> ?p ?o ?g. }

• W2965794037 endingPage "S1340" @default.
• W2965794037 startingPage "S1339" @default.
• W2965794037 abstract "Around 50% of cutaneous melanomas harbour therapeutically targetable BRAF V600 mutations. Reliable clinical biomarkers predicting duration of response to BRAF-targeted therapies are still lacking. Recent in vitro studies demonstrated that BRAF-MEK inhibitor therapy response is associated with tumour TERT promoter mutation status. We assessed this potential association in a clinical setting.The study cohort comprised 232 patients with metastatic or unresectable BRAF V600-mutated melanoma receiving combined BRAF/MEK inhibitor treatment, including a single-centre retrospective discovery cohort (N = 120) and a prospectively collected multicenter validation cohort (N = 112). Patients were excluded if they received BRAF or MEK inhibitors in an adjuvant setting, as monotherapy, or in combination with immunotherapy. Kaplan–Meier and univariate/multivariate Cox regression analyses were performed as appropriate.median age at first diagnosis was 54 years (range 16–84 years). The majority of patients were men 147/232 (63.4%). Most tumours harboured TERT promoter mutations (72%, N = 167). A survival advantage was observed in both progression-free survival (PFS) and overall survival (OS) for patients with TERT promoter-mutant versus wild-type tumours in both the discovery cohort (mPFS of 9.6 months [N = 87] vs 5.0 months [N = 33]; hazard ratio [HR] = 0.56 [95% confidence interval {CI} 0.33–0.96] and mOS of 33.6 months vs 15.0 months; HR = 0.47 [95%CI 0.32–0.70]) as well as the validation cohort (mPFS of 7.3 months [N = 80] vs 5.8 months [N = 32]; HR = 0.67 [95%CI 0.41–1.10] and mOS of 51.1 months vs 15.0 months; HR = 0.33 [95%CI 0.18–0.63]). In the pooled cohort of TERT promoter-mutant (N = 167) versus wild-type (N = 65) tumours, respectively, PFS was 8.9 versus 5.5 months, (HR = 0.62; 95%CI 0.45–0.87; P = 0.004), and OS was 33.6 versus 17.0 months, (HR = 0.51; 95%CI 0.35–0.75, P = 0.0001).In patients with melanoma receiving BRAF/MEK-targeted therapies, TERT promoter mutations are associated with longer survival. If validated in larger studies, TERT promoter mutation status should be included as a predictive biomarker in treatment algorithms for advanced melanoma." @default.
• W2965794037 created "2019-08-13" @default.
• W2965794037 creator A5001817812 @default.
• W2965794037 creator A5025733523 @default.
• W2965794037 creator A5027148574 @default.
• W2965794037 creator A5035097834 @default.
• W2965794037 creator A5042016074 @default.
• W2965794037 creator A5043951146 @default.
• W2965794037 creator A5063860490 @default.
• W2965794037 creator A5066121765 @default.
• W2965794037 creator A5074828414 @default.
• W2965794037 creator A5075961872 @default.
• W2965794037 creator A5076431340 @default.
• W2965794037 creator A5091552812 @default.
• W2965794037 date "2019-01-01" @default.
• W2965794037 modified "2023-10-17" @default.
• W2965794037 title "SU137DIFFERENCES DETWEEN AUDIT-C AND AUD PHENOTYPES REVEALED BY GENOME-WIDE ANALYSIS" @default.
• W2965794037 doi "https://doi.org/10.1016/j.euroneuro.2018.08.501" @default.
• W2965794037 hasPublicationYear "2019" @default.
• W2965794037 type Work @default.
• W2965794037 sameAs 2965794037 @default.
• W2965794037 citedByCount "0" @default.
• W2965794037 crossrefType "journal-article" @default.
• W2965794037 hasAuthorship W2965794037A5001817812 @default.
• W2965794037 hasAuthorship W2965794037A5025733523 @default.
• W2965794037 hasAuthorship W2965794037A5027148574 @default.
• W2965794037 hasAuthorship W2965794037A5035097834 @default.
• W2965794037 hasAuthorship W2965794037A5042016074 @default.
• W2965794037 hasAuthorship W2965794037A5043951146 @default.
• W2965794037 hasAuthorship W2965794037A5063860490 @default.
• W2965794037 hasAuthorship W2965794037A5066121765 @default.
• W2965794037 hasAuthorship W2965794037A5074828414 @default.
• W2965794037 hasAuthorship W2965794037A5075961872 @default.
• W2965794037 hasAuthorship W2965794037A5076431340 @default.
• W2965794037 hasAuthorship W2965794037A5091552812 @default.
• W2965794037 hasConcept C126322002 @default.
• W2965794037 hasConcept C143998085 @default.
• W2965794037 hasConcept C167135981 @default.
• W2965794037 hasConcept C207103383 @default.
• W2965794037 hasConcept C44249647 @default.
• W2965794037 hasConcept C50382708 @default.
• W2965794037 hasConcept C71924100 @default.
• W2965794037 hasConcept C72563966 @default.
• W2965794037 hasConceptScore W2965794037C126322002 @default.
• W2965794037 hasConceptScore W2965794037C143998085 @default.
• W2965794037 hasConceptScore W2965794037C167135981 @default.
• W2965794037 hasConceptScore W2965794037C207103383 @default.
• W2965794037 hasConceptScore W2965794037C44249647 @default.
• W2965794037 hasConceptScore W2965794037C50382708 @default.
• W2965794037 hasConceptScore W2965794037C71924100 @default.
• W2965794037 hasConceptScore W2965794037C72563966 @default.
• W2965794037 hasLocation W29657940371 @default.
• W2965794037 hasOpenAccess W2965794037 @default.
• W2965794037 hasPrimaryLocation W29657940371 @default.
• W2965794037 hasRelatedWork W1727188710 @default.
• W2965794037 hasRelatedWork W2118215538 @default.
• W2965794037 hasRelatedWork W2119154902 @default.
• W2965794037 hasRelatedWork W2133235702 @default.
• W2965794037 hasRelatedWork W2135028155 @default.
• W2965794037 hasRelatedWork W2203903734 @default.
• W2965794037 hasRelatedWork W2343768426 @default.
• W2965794037 hasRelatedWork W2906013683 @default.
• W2965794037 hasRelatedWork W2917746345 @default.
• W2965794037 hasRelatedWork W4213445964 @default.
• W2965794037 hasVolume "29" @default.
• W2965794037 isParatext "false" @default.
• W2965794037 isRetracted "false" @default.
• W2965794037 magId "2965794037" @default.
• W2965794037 workType "article" @default.